Literature DB >> 9834203

Highly efficient transduction of the green fluorescent protein gene in human umbilical cord blood stem cells capable of cobblestone formation in long-term cultures and multilineage engraftment of immunodeficient mice.

P B van Hennik1, M M Verstegen, M F Bierhuizen, A Limón, A W Wognum, J A Cancelas, J Barquinero, R E Ploemacher, G Wagemaker.   

Abstract

Purified CD34(+) and CD34(+)CD38(-) human umbilical cord blood (UCB) cells were transduced with the recombinant variant of Moloney murine leukemia virus (MoMLV) MFG-EGFP or with SF-EGFP, in which EGFP expression is driven by a hybrid promoter of the spleen focus-forming virus (SFFV) and the murine embryonic stem cell virus (MESV). Infectious MFG-EGFP virus was produced by an amphotropic virus producer cell line (GP+envAm12). SF-EGFP was produced in the PG13 cell line pseudotyped for the gibbon ape leukemia virus (GaLV) envelope proteins. Using a 2-day growth factor prestimulation, followed by a 2-day, fibronectin fragment CH-296-supported transduction, CD34(+) and CD34(+)CD38(-) UCB subsets were efficiently transduced using either vector. The use of the SF-EGFP/PG13 retroviral packaging cell combination consistently resulted in twofold higher levels of EGFP-expressing cells than the MFG-EGFP/Am12 combination. Transplantation of 10(5) input equivalent transduced CD34(+) or 5 x 10(3) input equivalent CD34(+)CD38(-) UCB cells in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice resulted in median engraftment percentages of 8% and 5%, respectively, which showed that the in vivo repopulating ability of the cells had been retained. In addition, mice engrafted after transplantation of transduced CD34(+) cells using the MFG-EGFP/Am12 or the SF-EGFP/PG13 combination expressed EGFP with median values of 2% and 23% of human CD45(+) cells, respectively, which showed that the NOD/SCID repopulating cells were successfully transduced. EGFP+ cells were found in all human hematopoietic lineages produced in NOD/SCID mice including human progenitors with in vitro clonogenic ability. EGFP-expressing cells were also detected in the human cobblestone area-forming cell (CAFC) assay at 2 to 6 weeks of culture on the murine stromal cell line FBMD-1. During the transduction procedure the absolute numbers of CAFC week 6 increased 5- to 10-fold. The transduction efficiency of this progenitor cell subset was similar to the fraction of EGFP+ human cells in the bone marrow of the NOD/SCID mice transplanted with MFG-EGFP/Am12 or SF-EGFP/PG13 transduced CD34(+) cells, ie, 6% and 27%, respectively. The study thus shows that purified CD34(+) and highly purified CD34(+)CD38(-) UCB cells can be transduced efficiently with preservation of repopulating ability. The SF-EGFP/PG13 vector/packaging cell combination was much more effective in transducing repopulating cells than the MFG-EGFP/Am12 combination.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9834203

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Adhesion, migration, and homing of murine hematopoietic stem cells and progenitors.

Authors:  Jose A Cancelas
Journal:  Methods Mol Biol       Date:  2011

2.  Engraftment of NOD/SCID mice with human CD34(+) cells transduced by concentrated oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114) envelope protein.

Authors:  J Gatlin; M W Melkus; A Padgett; P F Kelly; J V Garcia
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

3.  Evaluation of different protocols for gene transfer into non-obese diabetes/severe combined immunodeficiency disease mouse repopulating cells.

Authors:  Peter Ebeling; P Bach; U Sorg; A Schneider; T Trarbach; D Dilloo; H Hanenberg; S Niesert; S Seeber; T Moritz; M Flasshove
Journal:  J Cancer Res Clin Oncol       Date:  2006-10-20       Impact factor: 4.553

4.  In vivo analysis of retroviral enhancer mutations in hematopoietic cells: SP1/EGR1 and ETS/GATA motifs contribute to long terminal repeat specificity.

Authors:  Anke Wahlers; Peter F Zipfel; Maike Schwieger; Wolfram Ostertag; Christopher Baum
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

Review 5.  Clinical gene therapy in hematology: past and future.

Authors:  J Richter; S Karlsson
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

6.  Simultaneous infection with retroviruses pseudotyped with different envelope proteins bypasses viral receptor interference associated with colocalization of gp70 and target cells on fibronectin CH-296.

Authors:  E C MacNeill; H Hanenberg; K E Pollok; J C van der Loo; M F Bierhuizen; G Wagemaker; D A Williams
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.